Sanofi seizes Origimm for early-phase acne vaccine, opening a new front in mRNA strategy

Sanofi adds another thread to its mRNA strategy. Having previously bagged Translate Bio’s mRNA platform, Sanofi is now seizing Origimm Biotechnology to land a therapeutic acne vaccine that it plans to pair with the hot technology.

Origimm’s main prospect, ORI-001, is a therapeutic vaccine candidate against acne based on recombinant proteins that have recently entered the clinic. Sanofi is advancing this vaccine but is already looking beyond to track mRNA candidates. The plan is to develop additional antigen versions and use the mRNA platform in a phase 1/2 trial scheduled to begin in 2023.

Sanofi sees the mRNA platform as the key to unlocking the potential of Origimm’s work. The private Austrian biotech drew on research into the role Cutibacterium acnes would play in acne, working to control the growth of the bacteria and thus prevent it from damaging the skin.

Origimm used reverse functional screening to find protective antigens and therapeutic targets. In doing so, Origimm believes that it can select the most effective active ingredients for preventing or treating skin diseases. The book caught the attention of Sanofi.

RELATED: With $ 3.2 Billion, Sanofi Acquires mRNA Partner Translate Bio

“The acquisition of Origimm further expands our vaccine R&D pipeline with a first vaccine candidate against acne, a high medical need for millions of adolescents and adults,” said Thomas Triomphe, global director of Sanofi Pasteur , in a press release. “Welcoming Origimm to Sanofi broadens our field of expertise by providing extensive know-how in the field of skin microbiome and skin immunology.

Sanofi has the ability to improve treatment for a common disease with limited options. Isotretinoin, the oral medication also known as Accutane, may be effective against acne but comes with side effects that limit its use. Led by CEO Sanja Selak, Ph.D., formerly of Valneva, Origimm has worked for almost a decade to provide a better option.

Neither company has disclosed the terms of the deal. Origimm has kept a fairly low profile over its nine-year history, revealing Series A funding in 2016 without revealing the size of the tower, and additional cash from an Austrian funding plan in 2018, again without specify the amount. Biotechnology used the money to advance ORI-001, which entered preliminary clinical studies in the third quarter of 2021.

About Sally Dominguez

Check Also

Are vaccines linked to birth defects?

During pregnancy, it is natural to be concerned about the health of your baby. Eating …